

# Commercial & HealthCare Exchange PA Criteria Effective: June 3, 2020

#### Prior Authorization: Consensi

Products Affected: Consensi (Amlodipine and Celecoxib) oral tablets

#### Medication Description:

Consensi is a combination of amlodipine besylate, a calcium channel blocker, and celecoxib, a nonsteroidal antiinflammatory drug (NSAID), indicated for patients for whom treatment with amlodipine for hypertension and celecoxib for osteoarthritis are appropriate. Lowering blood pressure reduces the risk of fatal and nonfatal CV events, primarily strokes and myocardial infarction.

## Covered Uses: Hypertension and osteoarthritis

## Exclusion Criteria:

- 1. Known hypersensitivity to amlodipine, celecoxib, or any inactive ingredients of Consensi.
- 2. History of asthma, urticaria, or other allergic-type reactions after taking aspirin or other NSAIDs.
- 3. In the setting of CABG surgery
- 4. History of allergic-type reactions to sulfonamides

## **Required Medical Information:**

- 1. Diagnosis
- 2. Previous medications tried and failed

Age Restrictions: 18 years of age or older

#### Prescriber Restrictions: N/A

#### Coverage Duration: 12 months

#### **Other Criteria:**

- A. Patient has a diagnosis of both hypertension and osteoarthritis; AND
- B. Patient has had a trial and failure, to concurrent use of amlodipine and celecoxib as individual agents for at least 90 days.

# <u>References</u>:

1. Consensi (amlodipine and celecoxib) [prescribing information]. Hot Springs, AR: Burke Therapeutics, LLC; December 2019.

# Policy Revision history

Rev # Type of Change	Summary of Change	Sections Affected	Date
----------------------	-------------------	-------------------	------





1	New Policy	New Policy	All	6/3/2020		

Last Res. June 2020

